Literature DB >> 9663617

The importance of preventing hepatitis C virus infection among injection drug users in the United States.

M J Alter1, L A Moyer.   

Abstract

Injection drug use is the single most important risk factor for acquiring hepatitis C virus (HCV) infection. Injection drug users acquire this infection rapidly after initiating injection practices, and up to 90% of them are chronically infected with HCV. HCV infection is a major cause of chronic liver disease, and persons infected with HCV are at risk for chronic hepatitis, cirrhosis, and primary hepatocellular carcinoma, and they risk transmitting HCV infection to others. Preventive measures for HCV infection are limited. The heterogeneous nature of HCV and its ability to undergo rapid mutation appear to prevent the development of an effective neutralizing immune response, obstructing development of a vaccine. Prevention of HCV infection must rely on educational and programmatic efforts aimed at preventing drug use, providing substance abuse treatment for persons who inject illicit drugs, and encouraging safer injection practices. These efforts should include messages about the risk and prevention of all blood-borne pathogens, including HCV, hepatitis B virus, and human immunodeficiency virus.

Entities:  

Mesh:

Year:  1998        PMID: 9663617     DOI: 10.1097/00042560-199802001-00003

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  36 in total

1.  Hepatitis C among drug users: déjà vu all over again?

Authors:  D C Des Jarlais; A Schuchat
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

2.  Case-reporting of acute hepatitis B and C among injection drug users.

Authors:  Holly Hagan; Nadine Snyder; Eileen Hough; Tianji Yu; Shelly McKeirnan; Janice Boase; Jeffrey Duchin
Journal:  J Urban Health       Date:  2002-12       Impact factor: 3.671

3.  Hepatitis C screening and management practices: a survey of drug treatment and syringe exchange programs in New York City.

Authors:  Chi-Chi N Udeagu Pratt; Denise Paone; Rosalind J Carter; Marcelle C Layton
Journal:  Am J Public Health       Date:  2002-08       Impact factor: 9.308

4.  Health conditions among aging narcotics addicts: medical examination results.

Authors:  Yih-Ing Hser; Lillian Gelberg; Valerie Hoffman; Christine E Grella; William McCarthy; M Douglas Anglin
Journal:  J Behav Med       Date:  2004-12

5.  Quantifying potentially infectious sharing patterns among people who inject drugs in Baltimore, USA.

Authors:  M K Smith; M Graham; C A Latkin; S H Mehta; D A T Cummings
Journal:  Epidemiol Infect       Date:  2018-08-02       Impact factor: 2.451

6.  Prevalence and correlates of hepatitis C virus infection among street-recruited injection drug users in San Juan, Puerto Rico.

Authors:  Juan C Reyes; Héctor M Colón; Rafael R Robles; Eddy Rios; Tomás D Matos; Juan Negrón; Carmen Amalia Marrero; José M Calderón; Elizabeth Shepard
Journal:  J Urban Health       Date:  2006-11       Impact factor: 3.671

7.  Injection drug users and the provision of hepatitis C-related services in a nationwide sample of drug treatment programs.

Authors:  Zdravko P Vassilev; Shiela M Strauss; Janetta Astone; Don C Des Jarlais
Journal:  J Behav Health Serv Res       Date:  2004 Apr-Jun       Impact factor: 1.505

8.  HIV infection and the risk of diabetes mellitus.

Authors:  Adeel A Butt; Kathleen McGinnis; Maria C Rodriguez-Barradas; Stephen Crystal; Michael Simberkoff; Matthew Bidwell Goetz; David Leaf; Amy C Justice
Journal:  AIDS       Date:  2009-06-19       Impact factor: 4.177

9.  An HIV prevalence-based model for estimating urban risk populations of injection drug users and men who have sex with men.

Authors:  Spencer Lieb; Samuel R Friedman; Mary Beth Zeni; Dale D Chitwood; Thomas M Liberti; Gary J Gates; Lisa R Metsch; Lorene M Maddox; Tamara Kuper
Journal:  J Urban Health       Date:  2004-09       Impact factor: 3.671

10.  Hepatitis C for addiction professionals.

Authors:  Diana Sylvestre
Journal:  Addict Sci Clin Pract       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.